New drug

many

Novartis drug Afinitor® helps women with advanced breast cancer live significantly longer without their disease progressing

Everolimus combined with hormonal therapy more than doubled time without tumor growth and reduced risk of progression by 57% vs hormonal therapy alone[1]

Study shows everolimus significantly enhances benefit from hormonal therapy, representing important advance for women with postmenopausal ER+ breast cancer[1],[2]

Worldwide regulatory filings planned by the end of 2011 based on these data, marking the first submission for everolimus in breast cancer